Loading...
XLON
CNSL
Market cap5mUSD
Oct 13, Last price  
1.75GBP
Name

Omega Diagnostics Group PLC

Chart & performance

D1W1MN
XLON:CNSL chart
P/E
—
P/S
0.55
EPS
—
Div yield, %
—
Shrs. gr., 5y
13.27%
Rev. gr., 5y
-11.05%
Revenues
8m
-11.63%
0003,492,0005,438,0006,199,0007,902,00011,124,00011,262,89811,593,87012,105,31912,743,89614,246,93013,552,7268,756,7569,818,6628,734,8638,539,0007,546,000
Net income
-4m
L+173.95%
-73,000-85,0000238,000221,000187,00031,000527,000582,266692,851739,046571,912713,261-7,269,597974,253-6,828,312-2,104,310-1,409,000-3,860,000
CFO
-3m
L-2.38%
-63,000-78,000311,000600,000170,000322,000673,0001,014,9531,669,1071,247,8931,453,6762,011,324-828,497368,819547,607-2,419,589-3,229,000-3,152,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Omega Diagnostics Group PLC is a company dedicated to the development, manufacturing, and global supply of medical diagnostic products. Its extensive market reach includes the United Kingdom, mainland Europe, North and South America, India, various East Asian nations, Africa, and the Middle East, with distribution to approximately 75 countries worldwide. The business is structured into two main operating divisions: Health and Nutrition, and Global Health and Other. The Health and Nutrition segment is responsible for the research, creation, and production of diagnostic kits, such as those under the Foodprint brand, which are designed to detect immune responses to different foods. This division also offers clinical analysis services to the general public, medical clinics, and healthcare practitioners, in addition to supplying the Food Detective, a consumer-grade food sensitivity test. The Global Health and Other segment focuses on the research, development, production, and commercialization of diagnostic tools for infectious diseases. Key offerings from this segment include VISITECT CD4, an advanced rapid diagnostic test for managing HIV patients, the AbC-19 kit for COVID-19 antibody detection, and other COVID-19 antigen and antibody testing solutions. Omega Diagnostics' diverse range of products is provided to hospitals, medical clinics, laboratories, and other healthcare professionals. The company was established in 1987 and is headquartered in Alva, United Kingdom.

Key people

Colin King
Chief Executive Officer, Chief Operating Officer, Director · since 2017
Iain Logan
Group Financial Controller · since 2010
Kieron Harbinson
Group Finance Director, Company Secretary, Executive Director · since 2007
Jag Grewal
Group Sales and Marketing Director, Executive Director · since 2011
Karsten Brenzke
Site Manager of Omega Diagnostics GmbH · since 2012
Mike Gordon
Group Operations Director · since 2011
Prashant Maniar
Managing Director of Omega Dx (Asia) Pvt Limited · since 2011
Edward Valente
Group Research and Development Director · since 2011
Jamie Yexley
Site Manager of Genesis Diagnostics Limited and Cambridge Nutritional Sciences Limited · since 2012
Non-Executive Independent Director · since 2019
IPO date
Mar 18, 2004
Employees
91
Domiciled in
GB
Incorporated in
GB
Legal address
1 FLEET PLACE
LONDON, LND EC4M 7WS
GB
Headquarters
EDEN RESEARCH PARK
HENRY CRABB ROAD
LITTLEPORT, CAM CB6 1SE
GB
Previous name
OMEGA DIAGNOSTICS GROUP PLC

Valuation

Title
GBP in thousands, except ratios and share amounts
FYFYFYFYFYFYFY
2023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT